Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies, Inc. (NASDAQ: OSUR) is a medical devices company focused on point-of-need and home diagnostic tests and sample management solutions. The OraSure news stream on this page highlights company announcements, financial updates, product milestones, governance changes, and shareholder developments that shape the OSUR investment story.
News coverage commonly includes quarterly and year-to-date financial results, where OraSure reports net revenues, gross margins, operating performance, and the mix of diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product revenues. Earnings releases also discuss core business trends, cash and cash equivalents, and share repurchase activity, providing context on the company’s financial condition and capital allocation.
Investors and industry followers can also track product and innovation milestones, such as FDA submissions for the Sherlock rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections. Additional updates may cover launches of research-use products like HEMAcollect PROTEIN, agreements with partners such as GeneDx, and participation in initiatives like the ENDO1000 project.
Governance and corporate developments feature prominently in OraSure news. Recent items include board refreshment, the appointment of new independent directors, changes in board leadership, and the hiring of senior executives such as the Chief Commercial Officer. News also documents shareholder engagement, including communications from Altai Capital Management regarding board nominations and perspectives on company performance and strategy.
By following this OSUR news page, readers can review a chronological record of OraSure’s press releases and related items, covering earnings, product pipeline progress, strategic initiatives, board composition, and shareholder actions, all drawn from official company and partner announcements.
OraSure Technologies (NASDAQ: OSUR) has launched its InteliSwab® COVID-19 Rapid Test on Amazon, enhancing access to testing for U.S. consumers. The product, which is easy to use and requires no additional equipment, will be sold and fulfilled by Amazon with free Prime shipping. CEO Carrie Eglinton Manner emphasized that this partnership aims to broaden consumer reach and increase product awareness. The InteliSwab® test has received Emergency Use Authorization from the FDA for over-the-counter use, further supporting its use in nationwide testing initiatives.
OraSure Technologies schedules its earnings conference call for the third quarter of 2022 on November 8, 2022, at 5:00 pm ET. The press release detailing the financial results will be available at 4:05 pm ET on the same day. Participants can register for the call through a provided link, and a live webcast will be accessible via the company's investor relations page. For those who cannot attend, the call will be archived for 14 days. This event will provide insights into the company's financial performance and developments.
OraSure Technologies (NASDAQ: OSUR) has secured an $8.6 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a second-generation Ebola test utilizing the OraQuick® testing platform. The new test aims to enhance sensitivity, shelf life, and automation compared to the existing FDA-authorized version. OraSure's current Ebola Rapid Antigen Test is the only one with de novo FDA authorization since 2019 and has been widely used in Africa. This partnership underscores OraSure's commitment to addressing critical public health challenges.
OraSure Technologies (NASDAQ: OSUR) has been selected to provide OraQuick® In-Home HIV tests as part of the CDC’s ‘Together Take Me Home’ program, receiving $41.5 million over five years for community testing. The initiative targets populations disproportionately affected by HIV, aiming to deliver up to one million self-tests. This effort addresses barriers to HIV testing, such as privacy concerns and stigma, while empowering individuals to manage their health. The program is managed by Emory University in collaboration with various organizations.
OraSure Technologies (NASDAQ: OSUR) has announced a collaboration between its subsidiary Diversigen and Mars Petcare, aimed at enhancing understanding of pet health through microbiome research. This partnership involves sequencing microbiome samples from various breeds of cats and dogs as part of the Mars Petcare Biobank™ project. The collaboration aims to generate insights into microbial community composition to improve feline and canine health.
OraSure Technologies reported a strong financial performance for Q2 2022, with net revenues reaching $80.2 million, up 39% year-over-year, driven by a 213% increase in its Diagnostics business unit. InteliSwab® revenue surged to $43.1 million, representing 95% sequential growth. However, GAAP gross margins fell to 34.4%, down from 53.2% a year earlier. The company expects positive cash flow in Q4 2022, alongside strategic changes including a new CFO and Board adjustments.
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its earnings conference call scheduled for August 9, 2022, at 5:00 p.m. ET, to discuss the second quarter financial results and business developments. A press release detailing the financial results will be distributed at 4:05 p.m. ET, followed by the conference call at 5:00 p.m. Participants can join the call by dialing (866) 374-5140 using conference ID #11565698. A webcast of the call will also be available on the investor relations page of OraSure's website.
OraSure Technologies (OSUR) reaffirms its commitment to combat Hepatitis C through the Race to End Hep C initiative, which offers free testing at select NASCAR events. This initiative uses the OraQuick® HCV Rapid Antibody Test, providing results in 20 minutes. In 2021, 2.5% of 351 tested individuals were linked to care after a positive result. The CDC reports around 2.4 million adults in the U.S. have HCV, with 40% unaware of their infection. The program aims to improve awareness and access to treatment, aligning with World Hepatitis Day.
OraSure Technologies (NASDAQ: OSUR) announced the launch of its OMNIgene®•GUT DNA and RNA product, available to gut microbiome researchers for self-collection and stabilization of microbial DNA and RNA at ambient temperature. This product supports researchers in gene expression studies of gut microbes, aligning with OraSure's multiomics strategy and its subsidiary Diversigen's new sequencing services. With a strong track record in the genomics space, DNA Genotek's device portfolio is utilized globally in over 90 countries, further enhancing OraSure's market position.
OraSure Technologies, Inc. (NASDAQ: OSUR) announced on June 4, 2022, that its Board of Directors granted an inducement award to new CEO Carrie Eglinton Manner. This award includes:
- 814,830 restricted stock shares, vesting fully on June 4, 2024.
- 325,932 restricted stock shares, vesting in three annual installments starting June 4, 2023.
- 325,932 performance restricted stock units, vesting in three annual installments subject to performance conditions.
The award was granted under Nasdaq Rule 5635(c)(4), facilitating Ms. Manner's employment with the company.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
